Sa'ADatu Haruna Shinkafi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sa'ADatu Haruna Shinkafi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Abdulgafar Olayiwola Jimoh
Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto 840232, Sokoto State, Nigeria
2 shared publications - Albashir Tahir
Department of Pharmacology, Faculty of Basic Medical Sciences, Sa'adu Zungur University, Bauchi State, Nigeria
2 shared publications - Nura Abubakar
Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences Usmanu Danfodiyo University, Sokoto, 840232, Sokoto State, Nigeria
2 shared publications - Nura Bello
Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences Usmanu Danfodiyo University, Sokoto, 840232, Sokoto State, Nigeria
2 shared publications - Shuaibu Abdullahi Hudu
Center for Health Research, Northern Border University, Arar 91431, Saudi Arabia
2 shared publications - Abdulhakeem Abayomi Olorukooba
Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
Exploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review
Background: C–X–C motif chemokine ligand 13 (CXCL13) is a critical chemokine for lymphoid organization and immune cell migration during hepatitis B virus (HBV) infection. This systematic review assessed the function of CXCL13 in HBV immunoregulation, pathogenesis, genetic susceptibility, and treatment outcome. Methods: We systematically searched five databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify studies reporting on CXCL13 expression, genetic variants, and clinical outcomes in the context of HBV infection. Thirteen qualified studies were identified and assessed using standard quality appraisal instruments. Results: Data consistently supported the role of CXCL13 in recruiting CXCR5 T and B cells, conditioning germinal center–like reaction(s) as well as antiviral immune responses. Elevated serum CXCL13 levels correlated with better virological response, higher HBsAg clearance, and more favorable response to PegIFNα and nucleos(t)ide analogs. On the other hand, downregulation of CXCL13 was associated with immune tolerance, resistance failure, and disease persistence. Genetically, these polymorphic sites, such as rs355687 and rs76084459, have been associated with vaccine response, the possibility of transplacental transmission, and outcomes of antiviral therapy. Conclusion: CXCL13 is a key immunomodulatory factor in HBV infection and represents an excellent candidate predictive biomarker for treatment response and disease course. Prospective multicenter studies and laboratory research are needed to confirm its usefulness in clinical trials and to investigate therapeutic strategies targeting CXCL13.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
Open AccessExploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review
Background: C–X–C motif chemokine ligand 13 (CXCL13) is a critical chemokine for lymphoid organization and immune cell migration during hepatitis B virus (HBV) infection. This systematic review assessed the function of CXCL13 in HBV immunoregulation, pathogenesis, genetic susceptibility, and treatment outcome. Methods: We systematically searched five databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify studies reporting on CXCL13 expression, genetic variants, and clinical outcomes in the context of HBV infection. Thirteen qualified studies were identified and assessed using standard quality appraisal instruments. Results: Data consistently supported the role of CXCL13 in recruiting CXCR5 T and B cells, conditioning germinal center–like reaction(s) as well as antiviral immune responses. Elevated serum CXCL13 levels correlated with better virological response, higher HBsAg clearance, and more favorable response to PegIFNα and nucleos(t)ide analogs. On the other hand, downregulation of CXCL13 was associated with immune tolerance, resistance failure, and disease persistence. Genetically, these polymorphic sites, such as rs355687 and rs76084459, have been associated with vaccine response, the possibility of transplacental transmission, and outcomes of antiviral therapy. Conclusion: CXCL13 is a key immunomodulatory factor in HBV infection and represents an excellent candidate predictive biomarker for treatment response and disease course. Prospective multicenter studies and laboratory research are needed to confirm its usefulness in clinical trials and to investigate therapeutic strategies targeting CXCL13.
- Open Access
Predictors of Hepatitis B Vaccine Uptake among Healthcare Workers in Sokoto, Nigeria
Background Hepatitis B virus (HBV) infection is a major occupational hazard for healthcare workers (HCWs) in Nigeria, a high-prevalence country. With the HBV vaccine only integrated into the national childhood immunization program in 2004, most current HCWs are potentially unvaccinated and unprotected. This study aimed to determine the hepatitis B vaccine uptake rate and identify its predictors among HCWs in Sokoto State, Nigeria. Methods An analytical cross-sectional study was conducted between January and March 2023. A total of 804 HCWs were selected from primary, secondary, and tertiary health facilities using a multistage sampling technique. Data on sociodemographic characteristics, knowledge, attitude, and vaccine uptake were collected via a structured questionnaire. Multivariate logistic regression was used to identify independent predictors of vaccine uptake. Results Only 35.5% (285/804) of HCWs reported receiving at least one dose of the hepatitis B vaccine. Of these, just 51.6% (147/285) were fully vaccinated with three or more doses. Significant positive predictors of uptake included having a positive attitude towards the vaccine (aOR: 1.84; 95% CI: 1.19-2.84) and an employer recommending the vaccine at employment (aOR: 1.85; 95% CI: 1.15-2.98). Negative predictors included being a health assistant (aOR: 0.15; 95% CI: 0.03-0.91), working in a tertiary facility (aOR: 0.47; 95% CI: 0.24-0.93), having poor knowledge of HBV (aOR: 0.22; 95% CI: 0.07-0.69), and the absence of institutional advocacy (aOR: 0.62; 95% CI: 0.30-0.72). Conclusion Hepatitis B vaccination coverage among HCWs in Sokoto is critically low, exposing them to significant occupational risk. There is an urgent need for health authorities and hospital management to implement mandatory vaccination policies, coupled with targeted educational programs for vulnerable cadres, to improve uptake and protect this vital workforce.
Open AccessPredictors of Hepatitis B Vaccine Uptake among Healthcare Workers in Sokoto, Nigeria
Background Hepatitis B virus (HBV) infection is a major occupational hazard for healthcare workers (HCWs) in Nigeria, a high-prevalence country. With the HBV vaccine only integrated into the national childhood immunization program in 2004, most current HCWs are potentially unvaccinated and unprotected. This study aimed to determine the hepatitis B vaccine uptake rate and identify its predictors among HCWs in Sokoto State, Nigeria. Methods An analytical cross-sectional study was conducted between January and March 2023. A total of 804 HCWs were selected from primary, secondary, and tertiary health facilities using a multistage sampling technique. Data on sociodemographic characteristics, knowledge, attitude, and vaccine uptake were collected via a structured questionnaire. Multivariate logistic regression was used to identify independent predictors of vaccine uptake. Results Only 35.5% (285/804) of HCWs reported receiving at least one dose of the hepatitis B vaccine. Of these, just 51.6% (147/285) were fully vaccinated with three or more doses. Significant positive predictors of uptake included having a positive attitude towards the vaccine (aOR: 1.84; 95% CI: 1.19-2.84) and an employer recommending the vaccine at employment (aOR: 1.85; 95% CI: 1.15-2.98). Negative predictors included being a health assistant (aOR: 0.15; 95% CI: 0.03-0.91), working in a tertiary facility (aOR: 0.47; 95% CI: 0.24-0.93), having poor knowledge of HBV (aOR: 0.22; 95% CI: 0.07-0.69), and the absence of institutional advocacy (aOR: 0.62; 95% CI: 0.30-0.72). Conclusion Hepatitis B vaccination coverage among HCWs in Sokoto is critically low, exposing them to significant occupational risk. There is an urgent need for health authorities and hospital management to implement mandatory vaccination policies, coupled with targeted educational programs for vulnerable cadres, to improve uptake and protect this vital workforce.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2025 (1) , 3879562
Hepatitis B Vaccine Nonresponse and Associated Risk Factors: Insights From a Cohort Study
Hepatitis B virus (HBV) infection remains a critical global health issue, particularly in high‐burden regions with substantial global morbidity and mortality. Despite the efficacy of the hepatitis B vaccine in inducing immunity, a subset of vaccinated individuals fails to achieve adequate immunity. This study investigated the factors influencing immunological response to the hepatitis B vaccine among Nigerian adults. A cohort study was conducted at Usmanu Danfodiyo University Teaching Hospital, Sokoto, involving 307 participants aged 19–60 who had not previously received the hepatitis B vaccine. Data were collected using structured questionnaires assessing demographic characteristics, medical history, and lifestyle factors. Participants received GeneVac‐B, a recombinant hepatitis B vaccine, and 0‐, 1‐, and 2‐month schedule anti‐HB levels were measured post‐vaccination using a commercial enzyme‐linked immunosorbent assay (ELISA) kit (AccuDiag ELISA, Diagnostic Automation/Cortez Diagnostics, Inc., USA) to classify vaccine response. The association between demographic and lifestyle factors and vaccine response was analyzed using IBM SPSS Statistics (Version 25). Of the 307 participants, 209 received the first vaccine dose, and 192 completed all three doses. Anti‐HB quantification revealed that 94.3% of the participants achieved protective immunity (≥ 10 IU/L), while 5.7% were classified as nonresponders (< 10 IU/L). Statistical analysis indicated significant differences in the immune response based on gender ( p = 0.031), with females exhibiting higher mean anti‐HB levels than males. Negative correlations were observed between age and vaccine response ( ρ = −0.296, p < 0.01) and between body mass index (BMI) and response, although the latter was not statistically significant ( ρ = −0.131, p = 0.071). Prior tuberculosis, malaria, measles, smoking, and alcohol use showed no significant impact on the immune response, although recurrent malaria, measles, and smoking were associated with slightly lower mean antibody levels. The study indicates gender and age significantly influence hepatitis B vaccine response, with females and younger individuals demonstrating stronger immunity.
- 1 January 2025
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2025 (1) , 3879562
Open AccessHepatitis B Vaccine Nonresponse and Associated Risk Factors: Insights From a Cohort Study
Hepatitis B virus (HBV) infection remains a critical global health issue, particularly in high‐burden regions with substantial global morbidity and mortality. Despite the efficacy of the hepatitis B vaccine in inducing immunity, a subset of vaccinated individuals fails to achieve adequate immunity. This study investigated the factors influencing immunological response to the hepatitis B vaccine among Nigerian adults. A cohort study was conducted at Usmanu Danfodiyo University Teaching Hospital, Sokoto, involving 307 participants aged 19–60 who had not previously received the hepatitis B vaccine. Data were collected using structured questionnaires assessing demographic characteristics, medical history, and lifestyle factors. Participants received GeneVac‐B, a recombinant hepatitis B vaccine, and 0‐, 1‐, and 2‐month schedule anti‐HB levels were measured post‐vaccination using a commercial enzyme‐linked immunosorbent assay (ELISA) kit (AccuDiag ELISA, Diagnostic Automation/Cortez Diagnostics, Inc., USA) to classify vaccine response. The association between demographic and lifestyle factors and vaccine response was analyzed using IBM SPSS Statistics (Version 25). Of the 307 participants, 209 received the first vaccine dose, and 192 completed all three doses. Anti‐HB quantification revealed that 94.3% of the participants achieved protective immunity (≥ 10 IU/L), while 5.7% were classified as nonresponders (< 10 IU/L). Statistical analysis indicated significant differences in the immune response based on gender ( p = 0.031), with females exhibiting higher mean anti‐HB levels than males. Negative correlations were observed between age and vaccine response ( ρ = −0.296, p < 0.01) and between body mass index (BMI) and response, although the latter was not statistically significant ( ρ = −0.131, p = 0.071). Prior tuberculosis, malaria, measles, smoking, and alcohol use showed no significant impact on the immune response, although recurrent malaria, measles, and smoking were associated with slightly lower mean antibody levels. The study indicates gender and age significantly influence hepatitis B vaccine response, with females and younger individuals demonstrating stronger immunity.